Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Study of Erbitux™ (Cetuximab) in Pediatric Patients With Refractory Solid Tumors

NCT00110357 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT00110357
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00110357 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Study of Erbitux™ (Cetuximab) in Pediatric Patients With Refractory Solid Tumors
Lead sponsor
Eli Lilly and Company
Phase
Phase 1
Overall status
Completed
Start date
August 31, 2005
Completion date
March 31, 2008
Enrollment
48 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

cancer, refractory solid tumor